Teva Pharmaceutical Industries (NYSE:TEVA) EVP Richard Daniell Sells 17,295 Shares of Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Richard Daniell sold 17,295 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $547,732.65. Following the completion of the sale, the executive vice president directly owned 85,755 shares of the company’s stock, valued at $2,715,860.85. The trade was a 16.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Richard Daniell also recently made the following trade(s):

• On Tuesday, December 9th, Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $31.44 on Tuesday. The firm has a market capitalization of $36.15 billion, a PE ratio of 26.20, a PEG ratio of 10.39 and a beta of 0.72. The stock’s fifty day moving average is $33.01 and its 200 day moving average is $26.41. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. During the same period in the previous year, the firm earned $0.71 earnings per share. Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 results and FY‑2026 guidance remain a tailwind — Teva posted an EPS and revenue beat for the most recent quarter and set FY‑2026 EPS guidance of 2.570–2.770, with year‑over‑year revenue growth of ~11.4%. Those fundamentals help explain the stock’s strength today. MarketBeat TEVA coverage
• Neutral Sentiment: Management presented at the Leerink Global Healthcare Conference — a verbatim transcript of the presentation is available; investor focus will be on any pipeline updates, margin commentary or capital allocation remarks that could support the company’s outlook. Leerink presentation transcript
• Negative Sentiment: Significant insider selling disclosed (March 5 filings) — multiple executives sold shares at an average price of $31.67, including CEO Richard D. Francis (20,025 shares), EVP Richard Daniell (17,295), Placid Jover (14,150), Eric A. Hughes (9,533), Christine Fox (7,924) and Brian Savage (1,127). These disclosed sales reduce insider positions and may be read negatively by some investors; supporting SEC filings are available. Example SEC filing (CEO sale)
• Negative Sentiment: Media coverage highlights large CEO share sales — an American Banking News story flagged substantial CEO selling, which can amplify investor caution even when sales are routine or pre‑planned. Insider selling article

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Piper Sandler reaffirmed an “overweight” rating and set a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. Truist Financial increased their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Scotiabank boosted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday, January 29th. Finally, Bank of America upped their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus target price of $37.67.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC raised its stake in shares of Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after acquiring an additional 292 shares in the last quarter. Captrust Financial Advisors grew its stake in Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock worth $459,000 after purchasing an additional 302 shares in the last quarter. Banque Cantonale Vaudoise grew its stake in Teva Pharmaceutical Industries by 6.3% in the fourth quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock worth $160,000 after purchasing an additional 306 shares in the last quarter. Ethic Inc. increased its holdings in Teva Pharmaceutical Industries by 1.8% during the 4th quarter. Ethic Inc. now owns 18,127 shares of the company’s stock worth $566,000 after purchasing an additional 325 shares during the period. Finally, Allworth Financial LP raised its position in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.